
Case Study
Indication Sequencing: Assessing a Product’s Potential across Multiple Indications to Identify the Optimal Indication Sequencing
Our client was developing a novel cellular therapy with promising Phase I safety data and
Prescient developed a BD assessment framework to identify attractive candidates in an oncology indication with a high unmet need.
Our client was developing a novel cellular therapy with promising Phase I safety data and
Our client, a global specialty pharmaceutical company, was seeking to evaluate the clinical and commercial
Prescient helped accelerate, assure and simplify the client’s annual medical affairs strategic planning across its solid tumor franchise.
San Francisco
+1 415 230 8460New York
+1 973 347 7750Boston
+1 857 341 0341London
+44 20 8832 7900New Delhi
+91 11 7127 91701Beijing
+86 10 6562 9095